Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein tyrosine phosphatase non-receptor type 23 (PTPN23) is a cytosolic enzyme belonging to the PTP superfamily, which regulates the phosphorylation state of proteins on tyrosine residues. PTPN23 plays key roles in endosomal sorting via the ESCRT complex, acts as a tumor suppressor, and is involved in pre-mRNA splicing, ciliogenesis, and maintenance of cardiac T-tubule organization. It interacts with sarcomeric and membrane-associated proteins (e.g., α-actinin, dystrophin-glycoprotein complex) and participates in cytoskeletal anchoring in cardiomyocytes. Dysregulation of PTPN23 has been linked to neurodevelopmental disorders, structural brain anomalies, various cancers, and cardiac dysfunction. As with other protein tyrosine phosphatases, targeting PTPN23 for therapeutic modulation poses significant challenges due to the highly conserved nature of PTP active sites and potential for widespread effects on cellular signaling networks[1][2][4][5].
Inhibitors would block its phosphatase activity, potentially restoring or modulating signal transduction related to tumorigenesis, cellular differentiation, or other signaling pathways
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein tyrosine phosphatase non-receptor type 23 (PTPN23).